🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We had a great time at Aunt Jake's NYC making pasta with our oncology summer internship students! ASCO

Join OncLive LIVE July 23, 3:30 PM PT. Engage w/ Narjust Florez, MD, Edward S. Kim, MD, Eric K. Singhi, MD & vote in interactive polls! See how your answers align w/ experts. Follow OncLive.com & click 🔔 for alerts! #BTGLung2025 Eric K. Singhi, MD Edward S. Kim, MD, MBA, FACP, FASCO Narjust Florez, MD, FASCO

Calling all #thoracic #oncology leaders! We’re inviting early career investigators to submit an abstract for a chance to join us at the 7th Annual EGFR Resisters Research Summit EGFR Resisters Research Summit, (Nov 6–8 in Chicago). Please share this opportunity with your fellows, postdocs, or

Kicking off OncLive.com Bridging the Gaps in Lung Cancer with Small Cell Lung Cancer — Dr. Ravi Salgia reviews emerging biomarkers driving potential 2L+ therapeutic options for patients with ES-SCLC #BTGLung2025

‼️Polling Q2. Emerging treatment options in SCLC What do you see as the most promising strategy to improve OS in SCLC? #BTGLung2025 Jacob sands Triparna Sen (Sen-Lab) Narjust Florez, MD, FASCO Edward S. Kim, MD, MBA, FACP, FASCO Ana I. Velázquez Mañana, MD, MSc, FASCO OncLive.com

We are here with our biggest meeting yet! Join us for a live stream tomorrow at 3:30 pm PT Great faculty and challenging questions. OncLive.com Eric K. Singhi, MD Edward S. Kim, MD, MBA, FACP, FASCO #BTGLung2025

Dr. Julia Rotow MD discusses the fast evolving area of first line therapy for EGFR mutant NSCLC Covering recent press releases and OS updates OncLive.com Edward S. Kim, MD, MBA, FACP, FASCO Eric K. Singhi, MD Dana Farber's EGFR-Mutant Lung Cancer Center

Starting now at OncLive.com #BTGLung2025, this awesome panel on #EGFR w/ Julia Rotow MD, Ana I. Velázquez Mañana, MD, MSc, FASCO, Xiuning Le MD PhD, Elaine Shum + Joshua Sabari, MD! Perfect timing w/ +OS signal from FLAURA2!

Polling Q4. EGFRm NSCLC Beyond 1L‼️ Should EGFR inhibition be continued beyond progression? #BTGLung2025 Narjust Florez, MD, FASCO Edward S. Kim, MD, MBA, FACP, FASCO Balazs Halmos Xiuning Le MD PhD OncLive.com

Live from NY… it’s Joshua Sabari, MD to discuss uncommon #EGFR lung cancer #BTGLung2025 OncLive.com #lcsm

Drs. Elaine Shum & Ana I. Velázquez Mañana, MD, MSc, FASCO take on early stage #EGFR lung cancer updates & gaps! #BTGLung2025 #lcsm OncLive.com

A strong start to Day 2 of OncLive.com Bridging The Gap 2025 with a high-impact session on early-stage NSCLC chaired by Dr. Ravi Salgia. Featuring talks and discussions from donington, Tejas Patil, Christine Bestvina, Balazs Halmos, Heather Wakelee, and Eric K. Singhi, MD. #BTGLung2025

#lcsm What do you think?

Dr. Riess reminds us that it’s no longer just enough to say a “KRAS” mutation— nice figure here illustrating the spectrum of KRAS mutations and co-mutations in NSCLC. #BTGLung2025

Dr. Christine Garcia, MD, MPH nicely summarizes the evolving treatment landscape for patients with ROS1 positive NSCLC— incredible to see mPFS >45 months in this space! #BTGLung2025

Polling Q8. AGA NSCLC‼️ Given the recent approval of Teliso-V, in your practice, are you routinely testing for c-MET overexpression? If so, when? #BTGLung2025 OncLive.com Christine Garcia, MD, MPH Narjust Florez, MD, FASCO Edward S. Kim, MD, MBA, FACP, FASCO

Diving beyond EGFR in NSCLC with an excellent session chaired by Erin Schenk, MD, PhD, featuring a stellar lineup of talks on KRAS, BRAF, ROS1, MET, RET, and more! With insights from Christine Garcia, MD, MPH David Gandara Mihaela Aldea Jorge Nieva Jonathan Riess, MD MS OncLive.com #BTGLung2025 #LCSM #Oncology

Day two of #BTGLung2025 Dr. Christine Garcia, MD, MPH discusses treatment advances in ROS1 and MET altered lung cancers. Key area with recent approvals and many questions regarding biomarker testing particularly for MET altered NSCLC #LCSM Narjust Florez, MD, FASCO Edward S. Kim, MD, MBA, FACP, FASCO OncLive.com

Dr. Sandip Patel MD FASCO offers his thoughts on the 1L management of mNSCLC BOOKMARK this slide. #BTGLung2025 OncLive.com Narjust Florez, MD, FASCO Edward S. Kim, MD, MBA, FACP, FASCO

Dr. Fawzi Abu Rous, MD provides a “roadmap” for management after progression on immunotherapy. #BTGLung2025 OncLive.com